New Brunswick Scientific Co., Inc., Appoints James T. Orcutt As Chief Operating Officer
PR Newswire ~ February 27, 2004 ~ 3:34 pm EST
EDISON, N.J., Feb. 27 /PRNewswire-FirstCall/ -- New Brunswick Scientific Co., Inc. (Nasdaq: NBSC), today announced the promotion of James T. Orcutt, President of the Company, to the additional position of Chief Operating Officer. Mr. Orcutt joined the Company in May 2000 as President of its Life Science division and served in that capacity until his appointment as President of the Company on September 10, 2001.
David Freedman, Chairman and Chief Executive Officer of New Brunswick Scientific, stated "Jim Orcutt has taken on more and more responsibilities since becoming President and this promotion is in recognition of his leadership skills and his ability to innovate, especially after a very difficult year during which the market for life science equipment was very depressed During his tenure, Mr. Orcutt has focused on the implementation of strategic initiatives, team building and the development of depth in the Company's management structure. These efforts have positioned the Company for a strong resurgence as our traditional markets recover."
New Brunswick Scientific, an industry leader, provides a wide variety of research equipment and scientific instrumentation for use in medical, biological and chemical applications, as well as environmental research and commercial development of various goods. The Company's products are utilized in the creation, maintenance and control of physical and biochemical conditions required for the growth, detection and storage of microorganisms for the life sciences.
This press release includes statements that may constitute forward-looking statements made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. This information may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Further information concerning risk factors is described in the Company's Securities and Exchange Commission filings.
SOURCE New Brunswick Scientific Co.
/CONTACT: Investor Contact: Samuel Eichenbaum, Vice President, Finance
and Treasurer of New Brunswick Scientific Co., +1-732-650-2500, same@nbsc.com/
/Web site: nbsc.com /
(NBSC)
(END) |
